Search Results
Aug 20, 2026, 10:00 ET UPSHER-SMITH EXPANDS PORTFOLIO WITH LAUNCH OF GLATIRAMER ACETATE INJECTION
services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet
More news about: Upsher-Smith Laboratories, LLC
Aug 19, 2026, 18:00 ET Piramal Pharma Limited schließt die Übernahme einer Mehrheitsbeteiligung an Yapan Bio Private Limited ab
Yapan Bio von einem assoziierten Unternehmen von Piramal zu dessen Tochtergesellschaft. Damit stärkt Piramal seine Fähigkeit, komplexe, integrierte CDMO-Dienstleistungen für große Moleküle anzubieten. MUMBAI, Indien, 19.
More news about: Piramal Pharma Solutions
Aug 19, 2026, 14:56 ET Piramal Pharma Limited completa l'acquisizione di una quota di controllo di Yapan Bio Private Limited
biologici.Questa acquisizione trasforma Yapan Bio da società consociata di Piramal a sua controllata, migliorando la capacità della società di offrire servizi CDMO complessi e integrati per grandi molecole.MUMBAI, India, 19 agosto
More news about: Piramal Pharma Solutions
Aug 19, 2026, 11:21 ET Piramal Pharma Limited finalise l'acquisition d'une participation majoritaire dans Yapan Bio Private Limited
fait passer Yapan Bio du statut de société associée de Piramal à celui de filiale, renforçant ainsi la capacité de la société à proposer des services CDMO complexes et intégrés dans le domaine des grandes molécules. BOMBAY, Inde, 19
More news about: Piramal Pharma Solutions
Aug 19, 2026, 09:47 ET Zeon Lifesciences Strengthens U.S. Market Readiness with FDA Facility Registration and Global Quality Certifications
nutraceutical manufacturing and CDMO partners from India.FDA food facility registration is part of the regulatory framework for facilities manufacturing, processing
More news about: Zeon Lifesciences
Aug 19, 2026, 06:36 ET Piramal Pharma Limited completa la adquisición de una participación mayoritaria en Yapan Bio Private Limited
biológicos.Esta adquisición transforma a Yapan Bio de empresa asociada de Piramal a filial, mejorando así su capacidad para ofrecer servicios CDMO complejos e integrados para macromoléculas.BOMBAY, India, 19 de
More news about: Piramal Pharma Solutions
Aug 18, 2026, 15:44 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services. MUMBAI, India, Aug. 18, 2026 /PRNewswire/ --
More news about: Piramal Pharma Solutions
Aug 18, 2026, 15:36 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services. MUMBAI, India, Aug. 18, 2026 /PRNewswire/ --
More news about: Piramal Pharma Solutions
Aug 18, 2026, 13:21 ET Andelyn Biosciences to Implement Curator® Platform to Develop and Manufacture Gene Therapy AAV9-GM2 for Queen's University to Treat GM2 Gangliosidoses
2026 /PRNewswire/ -- Andelyn Biosciences, Inc., a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen's University to develop and manufacture AAV9-GM2, a gene therapy candidate for the treatment of GM2 gangliosidoses, such as
More news about: Andelyn Biosciences
Aug 18, 2026, 08:52 ET Orchestra Life Sciences Appoints Charles Conroy as Chief Operating Officer
bring a seasoned perspective to the decisions that sit between technical strategy and successful commercialization. Having built a radiopharmaceutical CDMO, led multi-site GMP operations, and managed capital allocation through periods of rapid growth, he understands how facility investments, operating models,
More news about: Orchestra Life Sciences
Aug 18, 2026, 07:00 ET Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
into a reputable cGMP compliant CDMO. Through this collaboration, Genprex aims to advance its diabetes gene therapy program toward clinical evaluation, focusing on the safety and efficacy required for upcoming toxicology studies."By partnering with an established CDMO, the Company gains access to
More news about: Genprex, Inc.
Aug 18, 2026, 03:04 ET WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
www.wuxibiologics.com.*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)*The winner of the "2026 Best Contract Development &
More news about: WuXi Biologics
Aug 14, 2026, 11:44 ET Aurisco Pharmaceutical est le premier fabricant mondial d'oligonucléotides génériques à avoir passé avec succès l'inspection de l'USFDA
Vutrisiran, Nusinersen, Eplontersen, etc.). Le site avait fait l'objet d'une inspection concluante de la part de l'USFDA en 2023 et propose des services CDMO, ainsi que des principes actifs génériques.Le Dr Li Jinliang, membre du conseil d'administration, a déclaré : « Cette inspection marque le début
More news about: Aurisco Pharmaceutical
Aug 12, 2026, 15:00 ET Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
generic oligonucleotides (Inclisiran, Vutrisiran, Nusinersen, Eplontersen, etc.). The site had been successfully inspected by USFDA in 2023 and offers CDMO services and generic APIs.Dr. Li Jinliang, Board Director, said "This inspection marks the beginning of a new of safe and affordable oligonucleotides
More news about: Aurisco Pharmaceutical
Aug 12, 2026, 15:00 ET Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
generic oligonucleotides (Inclisiran, Vutrisiran, Nusinersen, Eplontersen, etc.). The site had been successfully inspected by USFDA in 2023 and offers CDMO services and generic APIs.Dr. Li Jinliang, Board Director, said "This inspection marks the beginning of a new of safe and affordable oligonucleotides
More news about: Aurisco Pharmaceutical
Aug 11, 2026, 06:41 ET Cambrex Milan fête son 80e anniversaire avec la construction d'un nouveau centre de R&D d'une valeur de 30 millions de dollars
11 août 2026 /PRNewswire/ -- Cambrex, l'une des principales organisations de développement et de fabrication sous contrat (CDMO), a annoncé aujourd'hui le lancement de la construction d'un nouveau centre de recherche et développement (R&D) sur son site de Milan, en Italie.
More news about: Cambrex
Aug 11, 2026, 06:00 ET Cambrex Milan Celebrates 80th Anniversary with Construction of New $30 Million R&D Facility
N.J., Aug. 11, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the start of construction on a new research and development (R&D) facility at its Milan, Italy site. This $30 million investment
More news about: Cambrex
Aug 11, 2026, 06:00 ET Cambrex Milan Celebrates 80th Anniversary with Construction of New $30 Million R&D Facility
N.J., Aug. 11, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the start of construction on a new research and development (R&D) facility at its Milan, Italy site. This $30 million investment
More news about: Cambrex
Aug 11, 2026, 06:00 ET Cambrex Milan feiert 80-jähriges Jubiläum mit dem Bau einer neuen F&E-Anlage im Wert von 30 Millionen US-Dollar
11. August 2026 /PRNewswire/ -- Cambrex, ein weltweit führendes Auftragsentwicklungs- und -fertigungsunternehmen (CDMO), gab heute den Baubeginn für eine neue Forschungs- und Entwicklungseinrichtung (F&E) an seinem Standort in Mailand (Italien) bekannt. Diese Investition
More news about: Cambrex
Aug 11, 2026, 06:00 ET Cambrex Milan comemora seu 80º aniversário com a construção de novas instalações de P&D de US$ 30 milhões
11 de agosto de 2026 /PRNewswire/ -- A Cambrex, uma organização líder global em desenvolvimento e fabricação por contrato (CDMO), anunciou hoje o início da construção de uma nova instalação de pesquisa e desenvolvimento (P&D) em sua unidade de Milão, Itália. Este investimento
More news about: Cambrex
Aug 11, 2026, 06:00 ET Cambrex Milán celebra su 80.º aniversario con la construcción de un nuevo centro de I+D de $30 millones
11 de agosto de 2026 /PRNewswire/ -- Cambrex, una organización líder a nivel mundial dedicada al desarrollo y la fabricación por contrato (CDMO), ha anunciado hoy el inicio de las obras de construcción de un nuevo centro de investigación y desarrollo (I+D) en sus instalaciones de Milán, Italia.
More news about: Cambrex
Aug 11, 2026, 06:00 ET Cambrex Milán celebra su 80º aniversario con la construcción de un nuevo centro de I+D
11 de agosto de 2026 /PRNewswire/ -- Cambrex, una organización líder a nivel mundial dedicada al desarrollo y la fabricación por contrato (CDMO), ha anunciado hoy el inicio de las obras de construcción de un nuevo centro de investigación y desarrollo (I+D) en sus instalaciones de Milán, Italia.
More news about: Cambrex
Aug 11, 2026, 06:00 ET Cambrex 米蘭基地誌慶成立 80 週年，動工興建總值 3,000 萬美元的全新研發設施
米蘭研發設施擴建工程預計於 2027 年下半年完成。為配合未來業務增長，以及市場對 CDMO 服務日益增加的需求，Cambrex 亦已購入毗鄰基地的額外土地，為未來長遠擴展及持續創新預留充足空間。Cambrex Profarmico Milano 基地今年迎來成立 80 週年。多年來，該基地一直為全球客戶的藥物研發及生產提供支援，擁有悠久而卓越的往績。米蘭團隊早前聚首慶祝這一重要里程碑，一同回顧過去
More news about: Cambrex
Aug 11, 2026, 06:00 ET 캠브렉스 밀라노, 3000만 달러 규모의 신규 R&D 시설 건설로 창립 80주년 기념
밀라노 R&D 시설 확장 공사는 2027년 하반기에 완료될 것으로 예상된다. 캠브렉스는 향후 성장과 CDMO 서비스 수요 증가에 대응하기 위해 사업장 인근 부지를 추가로 매입했으며, 이를 통해 앞으로도 지속적인 확장과 혁신을 추진할 수 있는 기반을 확보했다.올해 창립 80주년을 맞은 캠브렉스 프로파마코 밀라노(Cambrex Profarmaco Milano) 사업장은
More news about: Cambrex
Aug 10, 2026, 06:34 ET Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
functions, improve operational discipline and establish scalable processes to support the continued growth of our CDMO platform and the broader Scinai organization."Scinai expanded its CDMO platform in the first quarter of 2026 through the acquisition of Recipharm Israel from Recipharm AB, adding a
More news about: Scinai Immunotherapeutics Ltd.